Acquired in November 2014, the site in Annan has been certified by the UK MHRA following extensive renovation and refitment
20 Sep 2016
Johnson Matthey, a leading provider of pharmaceutical services, active pharmaceutical ingredients (APIs) and catalyst technologies, announced today that its facilities in Annan, UK, have been approved for Good Manufacturing Practices (GMP) manufacturing following an extensive programme of renovation and refitment.
Johnson Matthey acquired the Annan facility in November 2014 in order to expand the Fine Chemicals Division's large volume capacity, in response to customer demand for controlled substance APIs and custom manufacturing services.
Ready for production
The company has made significant investments to refurbish the site, which is now fully equipped for GMP manufacturing. The certification follows a successful inspection by the UK Medicines and Healthcare products Regulatory Agency (MHRA), with no critical or major observations, and the site is now ready to commence production. As a result, Johnson Matthey Fine Chemicals is recruiting for 35 new vacancies at the Annan site across a variety of manufacturing and operational positions.
"Pharmaceutical companies rely on our global manufacturing network and portfolio of differentiating technologies for efficient and sustainable manufacturing of a variety of pharmaceutical ingredients," said John Fowler, Division Director at Johnson Matthey Fine Chemicals. "This GMP certification brings online valuable large scale capacity and further economies of scale to our expanding global API and pharma services offerings."
"This GMP certification brings online valuable large scale capacity and further economies of scale to our expanding global API and pharma services offerings."
Expanding in Europe
Johnson Matthey's investment in the Annan facilities represents an important part of the Fine Chemicals Division's ongoing growth strategy. The successful audit of the new site follows Johnson Matthey's recent expansion of its Cambridge, UK, facilities and acquisition of the Pharmorphix solid form sciences business within the European Custom Pharma Solutions offering.
Find out more
Nicholas Johnson, Strategic Marketing Director
+44 74 4253 9263